← Evidence map

ReviewOncogene2002

Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML.

Brian J DrukerPubMed ↗Publisher ↗

No numbers read from the abstract.

41 papers cite it

2002
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
this papercites it
Full record →Abstract, authors, funding and every citing paper · PMID 12476300